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ABSTRACT
Ribonuclease P (RNase P) is a Mg
2+-dependent
endoribonuclease responsible for the 5’-maturation
of transfer RNAs. It is a ribonucleoprotein complex
containing an essential RNA and a varying number
of protein subunits depending on the source: at
least one, four and nine in Bacteria, Archaea and
Eukarya, respectively. Since bacterial RNase P is
required for viability and differs in structure/subunit
composition from its eukaryal counterpart, it is a
potential antibacterial target. To elucidate the basis
for our previous finding that the hexa-arginine
derivative of neomycin B is 500-fold more potent
than neomycin B in inhibiting bacterial RNase P,
we synthesized hexa-guanidinium and -lysyl con-
jugates of neomycin B and compared their inhibi-
tory potential. Our studies indicate that side-chain
length, flexibility and composition cumulatively
account for the inhibitory potency of the aminogly-
coside-arginine conjugates (AACs). We also
demonstrate that AACs interfere with RNase
P function by displacing Mg
2+ ions. Moreover, our
finding that an AAC can discriminate between a
bacterial and archaeal (an experimental surrogate
for eukaryal) RNase P holoenzyme lends promise to
the design of aminoglycoside conjugates as selec-
tive inhibitors of bacterial RNase P, especially once
the structural differences in RNase P from the three
domains of life have been established.
INTRODUCTION
In the search for new therapeutic strategies to help reduce
or eliminate viral and bacterial infections, RNAs and
RNA-protein (RNP) complexes have come to the fore
as promising targets by virtue of their central roles in
key cellular processes (1–4). Ribonuclease P (RNase P),
a catalytic RNP complex (5–8), is one such example that
has attracted consideration as an antibacterial target
(9,10). RNase P is a Mg
2+-dependent endoribonuclease
primarily involved in 50-maturation of tRNAs in all three
domains of life (Figure 1). However, there are notable
diﬀerences in its structure and subunit composition
depending on the source (5–8). All RNase P holoenzymes
are RNPs made up of an essential RNase P RNA (RPR)
and a variable number of RNase P Protein (RPP)
subunits: at least one, four and nine in Bacteria,
Archaea and Eukarya, respectively. The observations
that bacterial RNase P (i) is essential for viability, (ii) is
present in low copy number and (iii) diﬀers in structure/
subunit composition from its eukaryal counterpart, have
justiﬁed studies to identify inhibitors of its activity (9,10).
Aminoglycosides (AGs) are naturally occurring, catio-
nic pseudo-oligo-saccharides that impair translational
ﬁdelity by binding the A-site in the bacterial 16S rRNA
(11–13). This ﬁnding provided the impetus to examine the
ability of AGs, with an established history as antibacterial
agents, to interfere with the function of other RNAs
(13,14). Indeed, various catalytic RNAs, including the
RNA moiety of bacterial RNase P, are inhibited by AGs
like neomycin and kanamycin (15–17). Various experi-
mental and computational studies on the mode of action
of AGs have revealed that the ability of AGs to interact
with several unrelated RNAs is due to their (i) multiple
positive charges that allow them to engage in electrostatic
interactions with RNAs, (ii) potential for hydrogen
bonding and (iii) conformational ﬂexibility that permits
induced ﬁt, which is often observed during RNA-ligand
interactions (13,18–20). Moreover, the striking coinci-
dence between the NH3
+–NH3
+ distances in the AGs and
the Mg
2+–Mg
2+ distances in the hammerhead ribozyme
(as revealed by molecular dynamics calculations) furn-
ished a structural basis for understanding how AGs can
readily displace metal ions and interfere with the function
of a target RNA (18).
Despite the ability of AGs to alter the function of
diﬀerent RNAs, their promiscuity as ligands stimulated
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selectivity while maintaining the aﬃnity for a desired
target RNA (13). An elegant illustration in this regard was
the guanidinylation of AGs that resulted in enhanced
discrimination among RNAs (21). Since RNA-binding
proteins utilize Arg-rich sequences for RNA recognition
(22,23), Lapidot and coworkers conjugated Arg residues
to neomycin B (NeoB), gentamycin or kanamycin back-
bones to construct aminoglycoside-arginine conjugates
(AACs) with the expectation that these compounds will
act as potent and selective peptidomimetics that would
prevent RNP assembly (24,25). Indeed, AACs were
proven to be eﬀective antagonists of the HIV Tat-TAR
RNA interaction. Our earlier investigation of AACs also
revealed that the hexa-arginine derivative of neomycin B
(NeoR6) was nearly 500-fold more potent than NeoB in
inhibiting bacterial RNase P and that NeoR6 was not as
eﬀective against human RNase P (26). In this report, we
describe our eﬀorts to examine structure-activity relation-
ships in AG-based inhibitors and to determine their
mechanism of inhibition of RNase P.
MATERIALS AND METHODS
Synthesis of AG derivatives
Reagent-grade solvents and distilled H2O were used
without further puriﬁcation unless otherwise stated.
The progress of reactions was monitored by thin layer
chromatography (using either UV or ninhydrin-based
detection) or electrospray ionization mass spectrometry
(ESI MS). Compounds were puriﬁed by either ﬂash
column (silica gel, 200–400 mesh) or ion-exchange
chromatography and were subsequently desalted by size-
exclusion chromatography. Puriﬁed compounds were
characterized by
1H and
13C NMR spectroscopy, FT-IR
spectroscopy, ESI-Q-TOF MS, LCT-TOF MS (Campus
Chemical Instrument Center, The Ohio State University),
C, H, N elemental analysis (QTI, Inc., Whitehouse, NJ,
USA) and Karl Fisher coulombic titration (QTI, Inc.,
Whitehouse, NJ, USA). A complete description of
the methods used for synthesis is provided elsewhere
(27, ‘Supplementary Data’).
RNase Pactivity assays inthe absence and presence
of inhibitors
Archaeal/bacterial RPRs and precursor tRNA
Tyr
(ptRNA
Tyr) were prepared by run-oﬀ in vitro transcription
using T7 RNA polymerase (28–31). RPRs, in water, were
folded according to the protocol outlined by Zahler et al.
(32). Bacterial and archaeal RNase P holoenyzmes were
reconstituted in vitro using their respective RPR and RPP
recombinant subunits. While Escherichia coli RNase P
served as the bacterial prototype, Methanothermobacter
thermautotrophicus (Mth) and Methanocaldococcus jan-
naschii (Mja) RNase P were used as the archaeal
representatives.
Bacterial and archaeal RNase P activities were mea-
sured in the absence and presence of various concen-
trations of inhibitors. Time-course assays were performed
to determine the initial velocities. All assays were
performed under multiple-turnover conditions using
ptRNA
Tyr as the substrate. In general, the order of
additions was as follows. The corresponding RPR and
RPP(s) were pre-incubated ( 10min) at the respective
assay temperature to allow holoenzyme assembly prior to
a 5-min incubation with the appropriate inhibitor. In
rescue experiments, either Mg
2+or RPP (in excess of that
used for holoenzyme generation) was added after addition
of the inhibitor. Reactions (10mL) were initiated by
addition of radiolabeled ptRNA
Tyr and terminated after
a deﬁned time period using 9mL of quench dye [0.05%
(w/v) bromophenol blue, 0.05% (w/v) xylene cyanol,
10mM EDTA, 7M urea] and 1mL phenol. Bacterial
RNase P reactions were performed at 378C either in a
‘high-salt’ buﬀer [10mM HEPES, 10mM Mg(CH3CO2)2,
400mM NH4CH3CO2, 5% (v/v) glycerol, and 0.01% (v/v)
IGEPAL, pH 7.2] or a ‘low-salt’ buﬀer [50mM Tris-HCl,
1mMNH 4Cl,10mMMgCl2,10mMspermidine,5%(w/v)
poly(ethylene glycol) 8000, pH 7.2]. Archaeal RNase P
reactions were performed at 558C in 10mM HEPES,
10mM Mg(CH3CO2)2, 800mM NH4CH3CO2, pH 7.2.
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Figure 1. A depiction of the assembly of the bacterial RNase P holoenzyme and its subsequent catalysis of ptRNA processing. The two broad
classes of potential inhibitors of bacterial RNase P and their sites of interference are indicated. This ﬁgure is adapted from an illustration in
Christian et al. (49).
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polyacrylamide gel containing 7M urea. The extent of
substrate cleaved was visualized using a phosphorimager
and quantitated with ImageQuant software (Molecular
Dynamics).
The data in Figures 3B, 4B and 5D represent mean and
standard deviation values calculated from at least three
independent measurements of initial velocities for a given
condition. Although the IC50 values, estimated from a
plot of initial velocities versus inhibitor concentration,
were reproducible, diﬀerent batches of stock solutions
did occasionally result in variations of up to 2-fold.
Despite these diﬀerences, the inhibition curves unequi-
vocally demonstrate the inhibitory trends with the various
neomycin derivatives.
RESULTS
Rationale
Our ﬁrst objective was to determine the structural aspects
of NeoR6 that contributed to its nearly 500-fold increased
potency compared to NeoB in inhibiting bacterial RNase
P assayed in a ‘low-salt’ buﬀer (IC50 of 60 and 0.125mM
for NeoB and NeoR6, respectively; 17,26). To examine the
eﬀects of side-chain length, ﬂexibility and composition, we
replaced the Arg side chains with either guanidinium or
lysyl moieties to yield NeoG6 or NeoK6, respectively
(Figure 2). Our second objective was to inquire if these
AG derivatives were either acting as peptidomimetics
that aﬀected bacterial RNase P holoenzyme assembly
or disrupting catalytically essential divalent metal ions
(Figure 1). The results of these studies are described
below.
Synthesis ofAG derivatives
Initially, we attempted to synthesize NeoR6 using
published protocols (25) but were unsuccessful. Hence,
we devised a diﬀerent synthetic route that yielded not
NeoR6 but a neomycin-penta-arginine conjugate (NeoR5;
see ‘Supplementary Data’). NeoR5 was used as the
reference in our comparative studies with NeoK6 and
NeoG6. While NeoK6 was synthesized using a new
procedure (see ‘Supplementary Data’), the synthesis of
NeoG6 was based on methods already described (33–35).
Elemental composition, NMR and mass spectrometric
analyses unambiguously conﬁrmed the identity of the end
products.
Structure-activity relationships in AG-based inhibitors
We ﬁrst deﬁne the expectations from a comparison of
NeoR5 versus either NeoG6 or NeoK6. In NeoG6, the
terminal guanidinuim groups in Arg are present albeit
without the advantages of the length and ﬂexibility
aﬀorded by the Arg side-chain and was therefore predicted
to be a poorer inhibitor than NeoR5. Similarly, if the
guanidinium functional groups in NeoR5 were involved in
hydrogen bonding (in addition to ionic or –) interac-
tions with RNase P, we postulated that replacing the
planar guanidinium moieties in NeoR5 with protonated
amines (as in NeoK6) should result in a decreased
inhibitory potential despite NeoK6 fulﬁlling length and
ﬂexibility criteria.
When we assayed the E. coli RNase P holoenzyme in a
‘high-salt buﬀer’ in the absence and presence of 2.5mMo f
the various neomycin derivatives, NeoR5 was clearly a
more potent inhibitor than NeoG6 or NeoK6 (Figure 3A,
lanes 2–5). The importance of the AG backbone was also
borne out by the ﬁnding that addition of 1mM arginine,
lysine or guanidine to the assay had no eﬀect on the E. coli
RNase P holoenzyme activity (Figure 3A, lanes 6–8).
To calculate the IC50 values, we determined the initial
velocities in the absence and presence of various concen-
trations of NeoB (the parental AG), NeoG6, NeoK6 and
NeoR5. The IC50 values are  400, 6, 3 and 0.5mM for
NeoB, NeoG6, NeoK6 and NeoR5, respectively
(Figure 3B). The trends observed are discussed in detail
later.
Mechanism ofaction of AG derivatives
There are at least two major strategies for inhibiting
bacterial RNase P (Figure 1; 9). The ﬁrst approach is to
disrupt formation of the holoenzyme (i.e. RNP complex)
by displacing or preventing the binding of the protein
cofactor to the catalytic RNA moiety. Such compounds
Figure 2. Structures of neomycin B (NeoB) and its guanidinium (NeoG6), lysyl (NeoK6) and argininyl (NeoR5) conjugates.
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might compete with the protein cofactor for binding the
RNA subunit. A compound that binds the RNA subunit
allosterically and changes its conformation, thereby
rendering it inaccessible for binding by the protein
cofactor, would also merit inclusion in this category.
The second approach involves using class II inhibitors
to interfere with RNase P catalysis, either by displacing
Mg
2+ ions required for catalysis or by preventing ptRNA
substrate binding. At the conclusion of our previous study
(26), we were unsure which of the above-mentioned routes
were employed by AACs in inhibiting E. coli RNase P.
It is important to note that we did eliminate the
possibility that non-speciﬁc interactions of AACs with the
ptRNA substrate aﬀect its processing by RNase P. When
we either included competitor RNAs (e.g. polyA) or
increased the concentration of the ptRNA substrate in the
assay, we found that these changes did not aﬀect the
inhibitory potential of AACs (26).
Since Litovchick et al. (24) reported that AACs inhibit
the binding of Tat protein to various targets, including
TAR RNA, probably by mimicking the conserved binding
motif (R49KKRRQRRR57) of the Tat protein, it seemed
possible that AACs, with their multiple Arg side chains,
could also mimic the conserved Arg residues in the
a2-helix of the bacterial RPP (36) and disrupt bacterial
RNase P holoenzyme assembly (9). We sought to test this
idea using stocks of AACs generously provided by Prof.
Aviva Lapidot, Weizmann Institute of Science. However,
protein rescue and RNase T1/V1 protection experiments
did not support this hypothesis (data not shown; 37).
Increasing the concentration of E. coli RPP did not rescue
E. coli RNase P activity from inhibition by AACs. Also,
the E. coli RPP’s footprint on its cognate RPR, as assessed
from protection of the RPR from cleavage by RNase T1/
V1, remained unchanged upon addition of AACs (data
not shown; 37). Taken together, we conclude that AACs
Figure 3. Inhibition of bacterial RNase P by diﬀerent neomycin B
derivatives. (A) Inhibition of in vitro reconstituted E. coli RNase P by
NeoR5, NeoK6 or NeoG6. As controls, free arginine (R), lysine (K)
and guanidine (G) were also tested. The lanes labeled ‘Sub.’ and ‘-Inh.’
indicate ptRNA
Tyr substrate that was incubated without any inhibitor
in the absence and presence of E. coli RNase P, respectively.
(B) Estimation of IC50 values for inhibition of E. coli RNase P by
NeoR5, NeoK6, NeoG6 and NeoB. The ptRNA processing activity
observed with a given concentration of the inhibitor is presented as
relative activity by using the activity observed without the inhibitor as
reference.
Figure 4. Mg
2+-mediated rescue of NeoR5 inhibition of bacterial
RNase P. (A) Lack of inhibition of E. coli RNase P by 1mM NeoR5 in
the presence of 30mM Mg
2+ (as compared to 10mM Mg
2+). The lane
labeled ‘Sub.’ indicates ptRNA
Tyr substrate that was incubated in the
absence of any enzyme or inhibitor. (B) Gradual rescue of NeoR5
inhibition by increasing the concentration of Mg
2+ in the assay. Since
bacterial RNase P holoenzyme activity decreases with increasing Mg
2+,
the relative activity presented refers to the ptRNA processing activity
observed in the presence of NeoR5 compared to that in its absence at
the speciﬁed Mg
2+ concentration.
700 Nucleic Acids Research, 2008, Vol. 36, No. 2do not compete with the protein cofactor for binding
to the RNA subunit.
RNase P-mediated cleavage is believed to occur via an
SN2 reaction in which a metal-hydroxide nucleophile
attacks the scissile phosphodiester linkage (5). Since AACs
do not disrupt bacterial RNase P holoenzyme formation,
we investigated whether AACs interfere with binding of
Mg
2+ ions critical for catalysis. It has been noted that
NeoB interferes with the binding of Mg
2+ ions to E. coli
RPR, the catalytic RNA moiety of E. coli RNase P
(17,38); this strategy also applies to inhibition of the group
I intron by NeoB (39). Our results demonstrate that
raising the concentration of Mg
2+ in the assay does rescue
E. coli RNase P from inhibition by NeoR5 (Figure 4A).
In the presence of 1mM NeoR5 and 10mM Mg
2+, there
is marked inhibition of E. coli RNase P activity; in
contrast, 1mM NeoR5 has almost no eﬀect at 30mM
Mg
2+. Note that activity of E. coli RNase P is lower at
30mM compared to 10mM Mg
2+, reﬂecting the decrease
in bacterial RNase P holoenyzme activity with increasing
Mg
2+ (37).
By calculating the initial velocities of E. coli RNase P at
increasing Mg
2+ concentrations (from 10 to 30mM) in
the absence and presence of 0.5mM NeoR5, we were able
to demonstrate that progressively increasing the con-
centration of Mg
2+ in the assay completely eliminates
inhibition of E. coli RNase P by NeoR5 (Figure 4B).
Similar rescue trends were observed when NeoG6 and
NeoK6 were used as inhibitors of E. coli RNase P and the
concentration of Mg
2+ in the assay gradually increased
(data not shown; 37).
Specificity oftargeting
Displacement of Mg
2+ in the E. coli RNase P holoenzyme
(136kDa) by NeoR5 (1.4kDa) is pivotal to the latter’s
ability to be a potent inhibitor. It is possible that these
critical metal ions are positioned at speciﬁc locations
in the RPR’s tertiary structure and that the potency of
a given inhibitor is related to its shape/charge comple-
mentarity with the Mg
2+-binding site(s) in the RPR.
A corollary would be that RNase P in the three domains
of life, with its varying RNP composition and structures,
might display diﬀerential susceptibility to NeoR5. Indeed,
this is the case.
Archaeal RNase P holoenzymes are made up of an
essential RPR and at least four RPPs, the latter initially
identiﬁed by mining databases of archaeal genome
sequences with eukaryal RPPs serving as queries (5–8).
Euryarchaeal RPRs have been classiﬁed into types A and
M based on secondary structure variations such as the
absence of a paired region P8 or a large L15 loop
(Figure 5B versus 5C; 40). We have recently succeeded in
reconstituting both type A and M archaeal RNase P
holoenzymes in vitro using recombinant subunits (29–31;
Pulukkunat et al., in preparation) and have demonstrated
robust ptRNA-processing activities. Since the archaeal
RNase P holoenzymes are typically assayed at 558Ci n
contrast to the assay temperature of 378C used for E. coli
RNase P, we ﬁrst tested the ability of NeoR5 to inhibit
E. coli RNase P at 558C and found that the IC50 value was
unchanged from that calculated at 378C (data not shown).
We then used in vitro reconstituted Mth and Mja RNase P
holoenzymes, as representatives of type A and M archaeal
RNase P, respectively, and examined their susceptibility to
inhibition by NeoR5. When we measured the initial
velocities of Mth and Mja RNase P in the absence and
presence of increasing concentrations of NeoR5, marked
diﬀerences became evident (Figure 5D). Mth RNase P was
inhibited quite signiﬁcantly and progressively up to 10mM
NeoR5 (similar inhibition by NeoR5 was found with
another type A RNase P from Pyrococcus furiosus; data
not shown). In stark contrast, Mja (type M) RNase P was
activated modestly (Figure 5D). This activation could
be due to stabilization of RNA structure for which there
Figure 5. Diﬀerential inhibition of archaeal RNase P by NeoR5. (A, B, and C) Secondary structure depictions of representative bacterial and
archaeal RPRs; arrowheads indicate universally conserved nucleotides (50). Helices (or paired regions) are labeled as P1, P2, etc., consecutively from
50 to 30; linkers are denoted as joining regions (e.g. J11/12 as the connector between P11 and P12); the L15 loop is speciﬁcally indicated. In panel C,
the empty boxes represent the structural elements that are absent in the type M archaeal RPR. (D) Inhibition of type A (Mth) and M (Mja) archaeal
RNase P by NeoR5. The ptRNA processing activity observed with a given concentration of the inhibitor is presented as relative activity by using the
activity observed without the inhibitor as reference.
Nucleic Acids Research,2008, Vol. 36,No. 2 701is precedent (41); in the absence of metal ions, both
polyamines and NeoB are known to promote hairpin
ribozyme cleavage perhaps by acting as surrogates for
metal ions (42).
The above results with type A and M archaeal RNase P
were somewhat expected since the L15 loop of E. coli
RNase P (Figure 5A), which is signiﬁcantly diminished in
type M (Mja) RNase P (Figure 5C), has been shown to be
important for inhibition by NeoB (17). Mutations in the
E. coli RPR’s L15 loop, that weaken Mg
2+ binding to
L15, resulted in a 3-fold increase in the IC50 for NeoB
(17). We therefore inquired if deleting L15 (and the P16/
P17 stems) would result in an E. coli RPR that would
be less susceptible to inhibition by NeoR5. Intriguingly,
such an E. coli RPR mutant (L15/P16/P17; Figure 5A),
when reconstituted with the E. coli Rpp to generate a
holoenzyme, was indistinguishable from its wild-type
counterpart in terms of turnover number and inhibition
by NeoR5 (IC50 0.5mM; data not shown). This result
indicates that the mutant RPR must somehow oﬀer an
alternative binding site(s) for NeoR5 that still permits its
interference with RNase P function. This also illustrates
the caveat of using deletion-based approaches to map
binding sites in RNAs for AGs and AACs, opportunistic
ligands that are adept at ﬁnding new binding pockets in
target RNAs (13).
DISCUSSION
Structure–activity relationships inAG derivatives that
inhibit bacterial RNase P
To rationalize the enhanced potency of NeoR5 compared
to NeoB in inhibiting bacterial RNase P activity (26), we
synthesized penta-argininyl (NeoR5), hexa-lysyl (NeoK6)
and hexa-guanidinium (NeoG6) conjugates of NeoB and
then determined how their ability to inhibit E. coli RNase
P is inﬂuenced by the characteristics of the side chains
attached to the neomycin backbone. Our studies revealed
that NeoR5 was the most potent inhibitor having
an IC50 0.5mM. Under identical assay conditions, both
NeoK6 and NeoG6 were  10-fold weaker while NeoB
was  800-fold weaker than NeoR5 (Figure 3B).
We infer that the potency of NeoR5 does not stem
from a single structural characteristic but instead is due
to a combination of side-chain length, ﬂexibility and
composition. The importance of side-chain length and
ﬂexibility is demonstrated by comparing NeoR5 with
NeoG6, in which the side chains are shortened to only the
guanidinium functional groups present in the Arg termini
of NeoR5 (Figure 2). Likewise, NeoK6 demonstrates the
importance of side-chain composition; its Lys residues,
with roughly the same side-chain length as Arg, have
terminal protonated amines but lack the guanidinium
moieties (Figure 2). NeoG6 and NeoK6 are both 10-fold
weaker than NeoR5 indicating that the Arg side chains in
NeoR5 are possibly involved in hydrogen bonding (and
possibly – interactions) in addition to electrostatic
interactions. Such a premise is consistent with the ﬁnding
that inhibition by Arg conjugates of neomycin exhibit very
weak salt dependence compared to NeoB; for instance, the
IC50 for inhibition of E. coli RNase P by NeoB increases
7-fold when the assay is performed in a ‘high-salt’ instead
of a ‘low-salt’ buﬀer (37).
While the nature of the moieties attached to AGs clearly
contributes to ﬁne tuning the inhibitory potency, the
parental backbone also plays a crucial role. AGs bind
RNAs by virtue of electrostatic and hydrogen bonding
interactions, and therefore some target speciﬁcity could be
expected when AGs with diﬀerent backbone structures
and geometries are compared. This notion has indeed been
borne out in studies with RNase P. For instance, NeoB
and paromomycin (Par) diﬀer only by a single substitution
of a hydroxyl group in NeoB for an amino group in Par,
yet this subtle diﬀerence results in Par being 6-fold weaker
than NeoB in inhibiting bacterial RPR (17). Thus, while
designing new AG conjugates, backbone variations must
also be considered.
Mechanism of inhibition of bacterial RNase P by
AG conjugates
AGs successfully interfere with the function of a target
RNA by either displacing metal ions or altering structure.
The inhibition of E. coli RPR activity by NeoB is
suppressed at high concentration of Mg
2+ and at high
pH where the amino groups in the AGs are not
protonated (17,37). Hence, the inhibitory potential of
AGs has been attributed to their ability to displace Mg
2+
ions, essential for RNase P catalysis, from high aﬃnity
binding sites in the RPR; parallels have been proposed to
account for the ability of AGs to inhibit other ribozymes
and even nucleic acid-metabolizing protein enzymes that
possess negatively charged pockets (39,43).
While such a mechanism of action seems likely for
NeoR5, we also entertained the idea that the Arg side-
chains splayed out from the neomycin backbone might
render NeoR5a potent peptidomimic that could compete
with the bacterial RPP for binding to its cognate RPR
and thereby disrupt assembly of the bacterial RNase
P holoenzyme (i.e. a class I inhibitor in the scheme
depicted in Figure 1). Such a possibility seemed reasonable
in light of the clustering of conserved and functionally
important Arg residues in a single a-helix of bacterial RPP
(36). However, increasing the concentration of bacterial
RPP did not abolish inhibition of bacterial RNase P by
AACs. Also, footprinting studies probing RNP interac-
tions in the bacterial RNase P holoenzyme, in the absence
and presence of AACs, revealed that AACs do not
dislodge the RPP from the holoenzyme. These ﬁndings
then left us with the recurring mechanistic theme that
AACs, like AGs, might function by displacing metal ions
from RNase P. Indeed, Mg
2+ rescue experiments demon-
strated that the inhibition of E. coli RNase P by NeoR5
was completely reversed by increasing Mg
2+ from 10 to
30mM in the assay (Figure 4).
Displacement of Mg
2+ by NeoR5 could inhibit RNase
P by aﬀecting RPR folding, ptRNA binding, or the
hydrolytic cleavage step. This mechanistic basis remains to
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ing strategy using a derivatized NeoR5 would help map
its binding site(s) on bacterial and archaeal RPRs and
thereby shed light on its mechanism of inhibition of E. coli
RNase P. In the absence of such information, we can only
speculate on its binding site(s).
Site-speciﬁc cleavages in the E. coli RPR mediated by
metal ions have been used to deduce the possible location
of metal ion-binding sites such as the L15 loop (44).
Interestingly, the inhibition of E. coli RPR by NeoB was
ascribed (at least in part) to its ability to displace Mg
2+
ions from L15; this inference was based on the modestly
decreased susceptibility of L15 mutants to inhibition
by NeoB and to lead-induced cleavage (17). L15 in the
bacterial RPR plays a role in substrate recognition,
cleavage site selection and metal ion binding (45);
however, we do not know if Mg
2+ ions bound to L15
are directly involved in cleavage of the scissile phospho-
diester linkage in the ptRNA substrate. The tertiary
structures of bacterial RPRs (46,47) illustrate the exquisite
tertiary interactions and overall folds but, in the absence
of a substrate, they did not reveal (as expected) the
locations of the metal ions essential for catalysis.
Nevertheless, there is growing biochemical evidence that
Mg
2+ ions bound to L15 are part of a metal ion cluster
that dictates the positioning of the catalytic metal ions
(45). Although we do not have direct evidence to suggest
that NeoR5 inhibits E. coli RNase P by binding to L15,
some support for this notion stems from the failure of
NeoR5 to inhibit an archaeal RNase P lacking the typical
L15 and the attached stems (Figure 5C). However, this
idea needs to be tempered by our ﬁnding that NeoR5
inhibits E. coli RNase P L15/P16/P17 mutant as
eﬀectively as it inhibits the wild type. Given the
opportunistic behavior of AGs (and possibly AACs),
this result does not conclusively eliminate the possibility of
NeoR5 binding to L15 in the wild-type E. coli RNase
P (see below).
Selectivity
Moderate/high aﬃnity and high selectivity for the target
RNA are essential attributes that are expected of small
molecules designed to interfere with RNA function
(1–4,13). AGs do not fulﬁll these criteria as borne out
by various studies. First, the availability of multiple
binding sites in a target RNA, or the presence of a fortu-
itous site in an unintended RNA that might oﬀer nearly
ideal electrostatic complementarity to accommodate the
AG ligands, makes it diﬃcult to ensure high speciﬁcity.
In fact, this type of binding ﬂexibility in the E. coli
RPR might underlie the ability of NeoR5 to inhibit the
E. coli RNase P holoenzyme reconstituted with either the
wild-type RPR or the L15/P16/P17 RPR, in which
the putative primary binding site for AGs is missing.
Second, high-resolution structural studies illustrate the
plasticity of AGs in adopting two diﬀerent conformations
while binding two distinct RNA targets (13).
Although the striking adaptability of AGs as RNA
ligands undermines their usage with high selectivity,
modiﬁcations to AGs have improved both aﬃnity and
speciﬁcity (13,21). In this study, we observed that NeoR5
can distinguish between type A and M archaeal RNase P
(Figure 5), a somewhat unexpected result since both
holoenzymes were reconstituted with an RPR and four
RPPs, which share sequence and structure homology.
While the type M RPRs are smaller by  10% relative to
the type A counterparts, the reconstituted holoenzymes
are roughly the same size. Furthermore, the presence of
12 or so universally conserved nucleotides at nearly
identical locations in the RPRs from all three domains
of life suggests a common RNA-mediated catalytic
reaction in all RNase P holoenzymes and implies that
the ability of NeoR5 to discriminate among them stems
from structural considerations rather than diﬀerences in
catalytic mechanisms. Even subtle variations in the RPR
structure, especially in the context of a diﬀerent suite
of RPR–RPP interactions in the respective RNase P
holoenzyme, would inﬂuence the number, location and
aﬃnity of metal-ion binding sites which in turn would
aﬀect the susceptibility to NeoR5. Another observation
highlighting the selectivity of AACs is the ability of
NeoR6 to discriminate between the eukaryal and the
bacterial translational machinery (48). Taken together, we
expect that the availability of the tertiary structures of
RNase P from the three domains of life might yet allow
design of AG conjugates that are highly selective for
bacterial RNase P.
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